Preloader

Focus Combined Solution:
FOCUS CGP + FOCUS 77 Liquid

The combined use of tissue and liquid biopsy maximizes biomarker detection rates. This comprehensive approach increases the likelihood of identifying clinically relevant alterations that may guide targeted treatment decisions.

In a study by Wade T. Iams et al., liquid biopsy identified variants that were not detected through solid tumor analysis in 9% of patients with metastatic pan-cancer disease (N=1,448).(¶)

Similarly, the ROME study (Marchetti et al., 2025) demonstrated that the integrated evaluation of tissue and liquid biopsy helped minimize missed actionable variants. When combined with recommendations from a Molecular Tumor Board, this approach contributed to improved treatment outcomes.(¶)

Test Contents:

See Focus CGP

See Focus 77 Liquid

//
Our customer support team is here to answer your questions!